Back

The impact of discontinuation of aspirin within 24 months among the high risk patients who are receiving prolonged dual antiplatelet therapy after implantation of second-generation drug-eluting stents

28 August 2020 (08:00 - 18:00)
Organised by:
Congress Presentation Part of: Pharmacology and Pharmacotherapy ePosters Antiplatelet Drugs ESC Premium Access ESC Congress 2020

About the speaker

Photo
Associate Professor Sung Woo Cho

Inje University Ilsan Paik hospital, Goyang (Korea (Republic of))

56 More presentations in this session

Presentation thumbnail
Tafolecimab, a novel potential long-acting PCSK9 monoclonal antibody: efficacy and safety in healthy and hypercholesterolemia subjects
Professor Y. Huo (Beijing, CN)
Abstract Slides
Presentation thumbnail
Vericiguat clinical pharmacology programme: biopharmaceutical properties and potential intrinsic and extrinsic factor effects
Doctor C. Becker (Wuppertal, DE)
Abstract Slides
Presentation thumbnail
Physiologically-based pharmacokinetic (PBPK) exploration of extrinsic factors influencing vericiguat pharmacokinetics
Doctor S. Frechen (Leverkusen, DE)
Abstract Slides
Presentation thumbnail
Long-term safety and efficacy of bempedoic acid in patients at high risk of atherosclerotic cardiovascular disease: results from the CLEAR Harmony open-label extension study
Doctor C. Ballantyne (Houston, US)
Abstract Slides
Presentation thumbnail
The effect of elevated triglycerides and purified eicosapentaenoic acid ethyl ester (EPA) for cardiovascular risk reduction in the UK Biobank population
Doctor D. Radenkovic (Greater London, GB)
Abstract Slides

Access the full session

Session thumbnail
Pharmacology and Pharmacotherapy ePosters

The Event

Event poster

ESC Congress 2020

28 August 2020 08:00 CET
You may be interested in
thumbnail
Webinar
Aspirin treatment for mitigating thrombotic risk across the cardiovascular risk continuum
thumbnail
Congress Presentation
Antithrombotic therapy in diabetes
thumbnail
Congress Session
State-of-the-art antithrombotic treatment in acute coronary syndromes: a paradigm shift?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources